Clinical trial
Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone…
NCT00324324 · OHSU Knight Cancer Institute, Other · Terminated
Key facts
| NCT number | NCT00324324 |
|---|---|
| Title | Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant |
| Official title | Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation |
| Lead sponsor | OHSU Knight Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma and 2 more |
| Intervention type | Drug |
| Interventions | moxifloxacin hydrochloride, Placebo |
| Enrollment | 240 |
| Start date | May 1, 2006 |
| Primary completion | Apr 1, 2007 |
| Completion | Dec 1, 2012 |
| First posted | May 11, 2006 |
| Last update posted | May 9, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: